NSC23005 sodium is a novel and effective p18 inhibitor (ED50=5.21 nM) in promoting Hematopoietic stem cells (HSCs) expansion in both murine and human models.

p18INK4C:5.21 nM (ED50)

NSC23005 sodium是一种新型INK4C (p18INK4C 或 p18) 小分子抑制剂 (p18SMIs)，最初通过in silico 3D 筛选发现。NSC23005 sodium在造血干细胞 (HSCs) 扩增中显示出最强的生物活性 (ED50=5.21 nM)。值得注意的是，NSC23005 sodium对32D细胞或HSCs没有明显的细胞毒性，也不会增加白血病细胞的增殖。NSC23005 sodium（ED50=5.21 nM），不促进白血病细胞的增殖。

NSC23005 sodium 通过抑制p18从而激活CDK4/6，专一性促进HSCs分裂。作为一种新型且有效的p18抑制剂，NSC23005 sodium 在促进小鼠和人类模型中HSCs扩张方面显示出良好效果，同时对HSCs没有明显的细胞毒性，并且不增加白血病细胞的增殖。

NSC23005 sodium is dissolved in DMSO and stored, and then diluted with appropriate medium before use[1]. c-Kit enriched bone marrow (BM) cells are cultured for 5 days with cytokine combination plus NSC23005 sodium or DMSO. As positive controls, primary uncultured bone marrow cells are treated by ultraviolet radiation (UV) for 10 minutes prior to the staining process for apoptosis analysis. Apoptosis and cell death are measured by AnnexinV and DAPI staining in the Annexin V-FITC Apoptosis Detection Kit. Apoptosis is measured on an FACS analyzer. The data is analyzed using FlowJo software[1].